← ANALYST RATINGS · TIPRANKS
DBV Technologies SA - American (DBVT): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $42.50, the highest $45.00, the lowest $40.00. The average is +369.6% from the last price of $9.05.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.50 → $9.00+5.9% | Hold | −0.6% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.50 → $9.00+5.9% | Hold | −0.6% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $10.00 → $9.00−10.0% | Hold | −0.6% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $9.50 → $8.50−10.5% | Hold | −6.1% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $10.00 → $9.00−10.0% | Hold | −0.6% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $9.50 → $9.00−5.3% | Hold | −0.6% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| Sam Slutsky★★★★★★★★★★#35 · hits 55% · avg +49.4% | LifeSci Capital | $45.00 | Buy | +397.2% | Reiterated | 30.09.26on TipRanks 08:55 | +2.0%next day −4.9% · 5 days −18.8% | ↗ |
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $40.00 | Buy | +342.0% | Reiterated | 21.09.26on TipRanks Sep 22 05:45 | −3.6%next day +4.4% · 5 days −2.8% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $51.00 | Buy | +463.5% | Reiterated | 17.07.26on TipRanks 07:17 | −0.1%next day −0.7% · 5 days −6.7% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $48.00 | Buy | +430.4% | Reiterated | 16.07.26on TipRanks Jul 17 08:25 | −4.9%next day −0.1% · 5 days −5.1% | ↗ |
| Jonathan Wolleben★★★★★★★★★★#249 · hits 53% · avg +23.6% | Citizens JMP | $55.00 | Buy | +507.7% | Reiterated | 30.06.26on TipRanks 06:08 | +1.7%next day −3.9% · 5 days +2.3% | ↗ |
| Rajan Sharma★★★★★★★★★★#5820 · hits 52% · avg +1.9% | Goldman Sachs | $7.94 → $5.81−26.8% | Sell | −35.8% | Reiterated | 09.04.26on TipRanks Apr 10 14:45 | −1.1%next day −3.7% · 5 days −6.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering DBV Technologies SA - American
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $46.00 at a price of $11.76 (+291.2%); now: $42.50 at $9.05 (+369.6%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 12 | 12 | 9 | 6 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 28.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.14 (from $-0.26 to $-0.09). Last quarter: $-0.12.
Best top-analyst consensus in the sector · Healthcare
About DBV Technologies SA - American
- CEO: Daniel Tassé
- Employees: 161
- BAtiment IRO, Châtillon, 92320, FR
- www.dbv-technologies.com
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
Data from the stock’s TipRanks forecast page, read 70 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗